Abstract
P-334 Lenvatinib plus checkpoint inhibitors (ICIs) versus sorafenib plus ICIs as first-line treatment for unresectable hepatocellular carcinoma with Child-Pugh B
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have